Search company, investor...
ScienceMatters company logo

ScienceMatters

sciencematters.io

Stage

Incubator/Accelerator | Alive

About ScienceMatters

ScienceMatters is an open science initiative dedicated to publishing single, well-validated observations. Articles go through triple-blind peer review.

Headquarters Location

Zurich,

Switzerland

Missing: ScienceMatters's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: ScienceMatters's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

ScienceMatters Patents

ScienceMatters has filed 1 patent.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

10/27/2015

Data management, NoSQL, Measurement, Network management, Network protocols

Application

Application Date

10/27/2015

Grant Date

Title

Related Topics

Data management, NoSQL, Measurement, Network management, Network protocols

Status

Application

ScienceMatters Frequently Asked Questions (FAQ)

  • Where is ScienceMatters's headquarters?

    ScienceMatters's headquarters is located at Zurich.

  • What is ScienceMatters's latest funding round?

    ScienceMatters's latest funding round is Incubator/Accelerator.

  • Who are the investors of ScienceMatters?

    Investors of ScienceMatters include MassChallenge.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.